FAITAVI - Major Late-Breaking Trial from EuroPCR 2025
Stephan Windecker and Flavio Ribichini review the outcomes of the FAITAVI trial, presented during the #europcr 2025 LBT session.
As coronary artery disease is the most common cardiac comorbidity in patients undergoing TAVI, the trial set out to evaluate whether physiology-guided decision-making could offer better clarity.
When performing diagnostic angiography before TAVI, clinicians often find intermediate coronary lesions that don’t obviously require revascularisation — so what's the right strategy in these cases?
FAITAVI is the first randomised trial comparing angiography-guided versus…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.